In contrast, high GCG expression was significantly associated with poorer survival in breast cancer (HR = 2.15, logrank p < 0.001), cervical squamous cell carcinoma (HR = 1.83, logrank p = 0.0008), esophageal adenocarcinoma (HR = 2.91, logrank p = 0.0038), head-neck squamous cell carcinoma (HR = 1.65, logrank p = 0.0015), lung squamous cell carcinoma (HR = 1.74, logrank p = 0.0011), ovarian cancer (HR = 1.81, logrank p = 0.0073), stomach adenocarcinoma (HR = 1.81, logrank p = 0.009), and uterine corpus endometrial carcinoma (HR = 2.35, logrank p < 0.0001). This evidence concerns the gene GCG and uterine corpus endometrial carcinoma.